Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18984595 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | December 2024 | July 2025 | Allow | 6 | 2 | 0 | No | No |
| 18957327 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | November 2024 | July 2025 | Allow | 8 | 2 | 0 | No | No |
| 18906588 | TEMPERATURE-RESPONSIVE VIRUS STORAGE SYSTEM | October 2024 | April 2025 | Allow | 6 | 1 | 0 | No | No |
| 18903162 | PREPARATION OF A THERAPEUTIC COMPOSITION FOR TREATING AUTOIMMUNE DISEASES | October 2024 | December 2025 | Allow | 14 | 4 | 1 | Yes | No |
| 18742215 | METHOD FOR MAKING PLURIPOTENT STEM CELLS | June 2024 | September 2024 | Allow | 3 | 0 | 0 | No | No |
| 18734664 | MESENCHYMAL STEM CELLS TREATED BY AT LEAST TWO OF CYTOKINES IL4, IL21, AND IL27, EXOSOMES AND USES THEREOF | June 2024 | October 2025 | Abandon | 16 | 2 | 1 | No | No |
| 18649790 | Adenoviral Vector Transduced Apheresis Product | April 2024 | January 2025 | Allow | 9 | 2 | 1 | Yes | No |
| 18405885 | SELECTIVE IMMUNODEPLETION OF ENDOGENOUS STEM CELL NICHE FOR ENGRAFTMENT | January 2024 | November 2025 | Abandon | 23 | 1 | 0 | No | No |
| 18386373 | ARTIFICIAL ANTIGEN-PRESENTING CELLS AND METHODS FOR PRODUCING AND USING THE SAME | November 2023 | July 2025 | Allow | 21 | 1 | 0 | No | No |
| 18381782 | TEMPERATURE-RESPONSIVE VIRUS STORAGE SYSTEM | October 2023 | November 2025 | Allow | 25 | 3 | 1 | Yes | Yes |
| 18358659 | GENETICALLY MODIFIED STEM CELLS | July 2023 | May 2025 | Allow | 21 | 1 | 0 | No | No |
| 18315782 | USING REPROGRAMMED, PERSONALIZED CANCER STEM CELLS AS A TRIPLE-KILLER CANCER TREATMENT | May 2023 | February 2025 | Abandon | 21 | 2 | 1 | No | No |
| 18316198 | MODIFIED B CELLS AND METHODS OF USE THEREOF | May 2023 | March 2024 | Allow | 10 | 2 | 1 | No | No |
| 18314778 | MODIFIED B CELLS AND METHODS OF USE THEREOF | May 2023 | October 2025 | Abandon | 30 | 0 | 1 | No | No |
| 18309489 | CELL CULTURE METHOD USING AMINO ACID-ENRICHED MEDIUM | April 2023 | January 2026 | Abandon | 33 | 1 | 1 | Yes | No |
| 18125691 | GLYCOSYLATED ANTIBODIES | March 2023 | October 2025 | Allow | 31 | 0 | 1 | No | No |
| 18246083 | TARGETED ANTIGEN DELIVERY SYSTEM AND USES THEREOF | March 2023 | January 2026 | Allow | 34 | 4 | 1 | Yes | No |
| 18174565 | COMPOSITIONS AND METHODS OF CELLULAR IMMUNOTHERAPY | February 2023 | September 2025 | Abandon | 30 | 1 | 0 | Yes | No |
| 18166700 | Activatable Cytokine Polypeptides and Methods of Use Thereof | February 2023 | April 2024 | Allow | 14 | 2 | 1 | Yes | No |
| 18106906 | REGULATORY B CELLS AND THEIR USES | February 2023 | September 2025 | Abandon | 31 | 1 | 0 | No | No |
| 18087618 | SELECTIVE IMMUNODEPLETION OF ENDOGENOUS STEM CELL NICHE FOR ENGRAFTMENT | December 2022 | October 2023 | Allow | 10 | 1 | 0 | No | No |
| 18069421 | Peptide for Inducing Regeneration of Tissue and Use Thereof | December 2022 | September 2025 | Abandon | 33 | 0 | 1 | No | No |
| 18002109 | CHIMERIC ANTIGEN RECEPTOR TARGETING BCMA AND USE THEREOF | December 2022 | February 2026 | Allow | 38 | 0 | 1 | No | No |
| 18000096 | NOVEL CONJUGATE OF IMMUNE-STIMULATING IL-2 ANALOG AND PREPARATION METHOD THEREOF | November 2022 | December 2025 | Allow | 36 | 2 | 0 | Yes | No |
| 17999370 | METHOD FOR THE TREATMENT OF VIRUS INFECTION WITH IVIG AND CONVALESCENT PLASMA | November 2022 | March 2026 | Abandon | 39 | 1 | 0 | No | No |
| 18057098 | STRATEGIES TO ASSESS AND/OR PRODUCE CELL POPULATIONS WITH PREDICTIVE ENGRAFTMENT POTENTIAL | November 2022 | December 2025 | Abandon | 37 | 1 | 1 | No | No |
| 17926542 | Ferritin Heavy Chain Subunit-Based Conjugates and Application Thereof | November 2022 | February 2026 | Abandon | 39 | 1 | 0 | No | No |
| 17923732 | ANTI-CANCER PROTEINS | November 2022 | March 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17921837 | ANTI-CANCER VACCINES AND RELATED THERAPY | October 2022 | March 2026 | Allow | 40 | 1 | 1 | Yes | No |
| 18050336 | Human Antibodies that Bind Lymphocyte Activation Gene-3 (LAG-3), and Uses Thereof | October 2022 | September 2025 | Abandon | 34 | 1 | 0 | No | No |
| 18047357 | MAMMALIAN CELLS COMPRISING INTEGRATED CAS9 GENES TO PRODUCE STABLE INTEGRATION SITES, AND MAMMALIAN CELLS COMPRISING STABLE INTEGRATION SITES AND OTHER SITES | October 2022 | February 2026 | Allow | 40 | 1 | 1 | No | No |
| 17919130 | Apoptosis inducing peptide (SSTP1) | October 2022 | February 2026 | Allow | 40 | 1 | 1 | No | No |
| 17938182 | PLASMID COMBINATION AND APPLICATION THEREOF IN PREPARING MODIFIED IMMUNE CELLS | October 2022 | August 2025 | Allow | 34 | 1 | 1 | Yes | No |
| 17936811 | EXPANSION OF NON-HAEMATOPOIETIC TISSUE-RESIDENT GAMMA DELTA T CELLS AND USES OF THESE CELLS | September 2022 | July 2025 | Allow | 34 | 1 | 1 | Yes | No |
| 17934811 | ACTIVATABLE CYTOKINE POLYPEPTIDES AND METHODS OF USE THEREOF | September 2022 | April 2024 | Allow | 19 | 2 | 1 | No | No |
| 17913751 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING CORONAVIRUSES | September 2022 | January 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17948313 | ALLELE EDITING AND APPLICATIONS THEREOF | September 2022 | March 2025 | Allow | 30 | 1 | 0 | No | No |
| 17931576 | CELLULAR TARGETED ACTIVE INGREDIENT DELIVERY SYSTEM | September 2022 | April 2024 | Allow | 19 | 2 | 0 | No | No |
| 17910967 | METHODS AND USE OF CHIMERIC PROTEINS | September 2022 | November 2025 | Allow | 38 | 1 | 0 | Yes | No |
| 17930231 | IMMUNOLOGICAL DETECTION OF ALTERED CELLS | September 2022 | March 2026 | Abandon | 42 | 2 | 1 | No | No |
| 17823448 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | August 2022 | February 2024 | Allow | 17 | 3 | 0 | Yes | No |
| 17823445 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | August 2022 | January 2024 | Allow | 17 | 2 | 0 | No | No |
| 17823454 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | August 2022 | February 2024 | Allow | 17 | 3 | 0 | No | No |
| 17823419 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | August 2022 | July 2024 | Allow | 22 | 5 | 0 | No | No |
| 17821703 | NK CELLS OR T CELLS EXPRESSING HEMATOPOIETIC GROWTH FACTOR RECEPTORS AND METHODS OF USE | August 2022 | May 2024 | Abandon | 29 | 2 | 1 | No | No |
| 17817751 | HUMAN MONOCLONAL ANTIBODIES TO FUCOSYL-GM1 AND METHODS FOR USING ANTI-FUCOSYL-GM1 ANTIBODIES | August 2022 | May 2025 | Allow | 33 | 1 | 1 | No | No |
| 17817885 | COMPOSITION FOR DETERMINATION OF CELL-MEDIATED IMMUNE RESPONSIVENESS | August 2022 | April 2025 | Abandon | 32 | 1 | 0 | No | No |
| 17817217 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | August 2022 | May 2023 | Allow | 9 | 3 | 0 | No | No |
| 17817239 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | August 2022 | May 2023 | Allow | 9 | 3 | 0 | No | No |
| 17817247 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | August 2022 | June 2023 | Allow | 10 | 2 | 0 | No | No |
| 17817279 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | August 2022 | October 2022 | Allow | 2 | 1 | 0 | No | No |
| 17817232 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | August 2022 | February 2023 | Allow | 6 | 3 | 0 | Yes | No |
| 17817273 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | August 2022 | June 2024 | Allow | 22 | 4 | 0 | Yes | No |
| 17817276 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | August 2022 | October 2022 | Allow | 2 | 7 | 0 | No | No |
| 17817281 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | August 2022 | October 2022 | Allow | 2 | 1 | 0 | No | No |
| 17817226 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | August 2022 | November 2022 | Allow | 3 | 2 | 0 | No | No |
| 17817207 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | August 2022 | November 2022 | Allow | 4 | 3 | 0 | No | No |
| 17872741 | COMBINED ORGAN AND HEMATOPOIETIC CELLS FOR TRANSPLANTATION TOLERANCE OF GRAFTS | July 2022 | February 2025 | Allow | 30 | 1 | 0 | No | No |
| 17758947 | GENETICALLY ENGINEERED T CELLS EXPRESSING BCMA-SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF IN CANCER THERAPY | July 2022 | January 2026 | Abandon | 42 | 0 | 1 | No | No |
| 17861534 | METHODS AND COMPOSITION FOR PRODUCING AND USING IMMUNE CELLS AND STEM CELLS FOR CELL-BASED THERAPIES | July 2022 | July 2025 | Allow | 36 | 1 | 1 | No | No |
| 17791137 | MULTISPECIFIC ANTI-CLAUDIN-18.2 CONSTRUCTS AND USES THEREOF | July 2022 | January 2026 | Abandon | 42 | 0 | 1 | No | No |
| 17856997 | GENERATING CIK NKT CELLS FROM CORD BLOOD | July 2022 | October 2023 | Allow | 16 | 2 | 1 | Yes | No |
| 17856800 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | July 2022 | August 2022 | Allow | 2 | 1 | 0 | No | No |
| 17856793 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | July 2022 | April 2023 | Allow | 9 | 4 | 0 | No | No |
| 17856806 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | July 2022 | June 2023 | Allow | 12 | 4 | 0 | Yes | No |
| 17810482 | CLOSED PROCESS FOR EXPANSION AND GENE EDITING OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | July 2022 | February 2023 | Allow | 8 | 2 | 0 | No | No |
| 17810540 | CLOSED PROCESS FOR EXPANSION AND GENE EDITING OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | July 2022 | March 2023 | Allow | 8 | 4 | 0 | Yes | No |
| 17810542 | CLOSED PROCESS FOR EXPANSION AND GENE EDITING OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | July 2022 | June 2023 | Allow | 12 | 2 | 0 | Yes | No |
| 17810537 | CLOSED PROCESS FOR EXPANSION AND GENE EDITING OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | July 2022 | March 2023 | Allow | 8 | 2 | 0 | Yes | No |
| 17848590 | USE OF PRE T ALPHA OR FUNCTIONAL VARIANT THEREOF FOR EXPANDING TCR ALPHA DEFICIENT T CELLS | June 2022 | November 2025 | Allow | 41 | 2 | 1 | Yes | No |
| 17786039 | LAG3 ANTAGONIST CELL BASED POTENCY ASSAY | June 2022 | December 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17842212 | SYSTEMS AND METHODS FOR CELL CULTURING | June 2022 | January 2025 | Allow | 31 | 1 | 0 | No | No |
| 17827089 | PREPARATION OF A THERAPEUTIC COMPOSITION FOR TREATING AUTOIMMUNE DISEASES | May 2022 | March 2025 | Abandon | 33 | 7 | 1 | Yes | No |
| 17804239 | GENERATION OF CTL LINES WITH SPECIFICITY AGAINST MULTIPLE TUMOR ANTIGENS OR MULTIPLE VIRUSES | May 2022 | June 2025 | Allow | 36 | 1 | 1 | No | No |
| 17825175 | METHODS OF DETERMINING PROGNOSIS OF SEPSIS AND TREATING SAME | May 2022 | December 2025 | Abandon | 43 | 1 | 1 | No | No |
| 17746097 | ANTIBODY PRODUCING MICROFLUIDIC DEVICES | May 2022 | December 2025 | Abandon | 43 | 1 | 1 | No | No |
| 17734907 | Optimization of Antibodies that Bind Lymphocyte Activation Gene-3 (LAG-3), and Uses Thereof | May 2022 | March 2025 | Abandon | 35 | 0 | 1 | No | No |
| 17769467 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY | April 2022 | December 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17698920 | METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION | March 2022 | March 2025 | Abandon | 36 | 0 | 1 | No | No |
| 17691477 | METHODS FOR STEM CELL TRANSPLANTATION | March 2022 | March 2026 | Allow | 48 | 2 | 0 | No | Yes |
| 17681665 | DEVELOPING AN EFFICIENT HYBRIDOMA PLATFORM FOR THERAPEUTIC ANTIBODY DISCOVERY | February 2022 | July 2025 | Allow | 41 | 2 | 1 | No | No |
| 17669891 | ANTI-LAG3 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS | February 2022 | May 2024 | Allow | 27 | 0 | 0 | No | No |
| 17586698 | PROCESS FOR T CELL EXPANSION | January 2022 | July 2025 | Allow | 42 | 1 | 1 | No | No |
| 17628032 | COMPOSITION AND METHOD FOR ADOPTIVE IMMUNOTHERAPY | January 2022 | October 2025 | Allow | 45 | 1 | 1 | No | No |
| 17578172 | SELECTIVE EXPANSION OF DIFFERENT SUBPOPULATIONS OF T CELLS BY THE ALTERATION OF CELL SURFACING SIGNALS AND SIGNAL RATIO | January 2022 | December 2024 | Allow | 34 | 1 | 0 | No | No |
| 17574483 | TUMOR-ACTIVATED ALLOREACTIVE AND XENOREACTIVE T CELLS AND THEIR USE IN IMMUNOTHERAPY AGAINST CANCER | January 2022 | February 2026 | Allow | 49 | 1 | 1 | No | No |
| 17569943 | CULTURE CONTAINER, METHOD FOR CULTURING LYMPHOCYTES, CULTURE-CONTAINER PRODUCTION METHOD, AND SOLID-PHASING APPARATUS | January 2022 | December 2024 | Allow | 35 | 2 | 0 | Yes | No |
| 17567470 | BISPECIFIC ANTIBODIES FOR USE IN STEM CELL TRANSPLANTATION | January 2022 | December 2024 | Abandon | 35 | 1 | 0 | No | No |
| 17544542 | Human Antibodies that Bind Lymphocyte Activation Gene-3 (LAG-3), and Uses Thereof | December 2021 | July 2022 | Allow | 8 | 1 | 0 | No | No |
| 17544534 | Human Antibodies that Bind Lymphocyte Activation Gene-3 (LAG-3), and Uses Thereof | December 2021 | July 2022 | Allow | 7 | 1 | 0 | No | No |
| 17531983 | METHOD FOR DETECTING TARGET MOLECULE | November 2021 | August 2025 | Allow | 45 | 1 | 1 | No | No |
| 17525714 | METHODS AND COMPOSITIONS FOR INFUSION OF TRANSIENTLY ENGRAFTING, SELECTED POPULATIONS OF ALLOGENEIC LYMPHOCYTES TO TREAT CANCER | November 2021 | March 2025 | Allow | 40 | 1 | 1 | No | No |
| 17522538 | GENETICALLY MODIFIED STEM CELLS | November 2021 | April 2023 | Allow | 17 | 2 | 0 | No | No |
| 17504656 | CONDITIONING AGENTS FOR USE IN ALLOGENEIC HEMATOPOETIC STEM CELL TRANSPLANTATION | October 2021 | August 2025 | Allow | 46 | 3 | 1 | Yes | No |
| 17494633 | T CELL MANUFACTURING COMPOSITIONS AND METHODS | October 2021 | November 2024 | Allow | 37 | 1 | 1 | No | No |
| 17493411 | STEM CELL FACTOR INHIBITOR | October 2021 | December 2024 | Abandon | 38 | 0 | 1 | No | No |
| 17490691 | ACTIVATION OF MARROW INFILTRATING LYMPHOCYTES IN HYPOXIC ALTERNATING WITH NORMOXIC CONDITIONS | September 2021 | November 2024 | Allow | 37 | 1 | 0 | No | No |
| 17480525 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | September 2021 | February 2022 | Allow | 4 | 1 | 0 | No | No |
| 17480596 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | September 2021 | April 2022 | Allow | 7 | 1 | 0 | No | No |
| 17480587 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | September 2021 | February 2022 | Allow | 5 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BELYAVSKYI, MICHAIL A.
With a 44.1% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 19.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner BELYAVSKYI, MICHAIL A works in Art Unit 1644 and has examined 1,454 patent applications in our dataset. With an allowance rate of 55.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 35 months.
Examiner BELYAVSKYI, MICHAIL A's allowance rate of 55.7% places them in the 16% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by BELYAVSKYI, MICHAIL A receive 1.84 office actions before reaching final disposition. This places the examiner in the 43% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by BELYAVSKYI, MICHAIL A is 35 months. This places the examiner in the 38% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +37.0% benefit to allowance rate for applications examined by BELYAVSKYI, MICHAIL A. This interview benefit is in the 85% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 22.4% of applications are subsequently allowed. This success rate is in the 28% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 33.7% of cases where such amendments are filed. This entry rate is in the 50% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 26.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 30% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 73.0% of appeals filed. This is in the 61% percentile among all examiners. Of these withdrawals, 73.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 50.0% are granted (fully or in part). This grant rate is in the 46% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 5.0% of allowed cases (in the 86% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.5% of allowed cases (in the 55% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.